Location Directory

Clinical trials in Atlanta, Georgia

This page shows live ClinicalTrials.gov search results for Atlanta, Georgia, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

13062

Shown on this page

Current sort

Institutions in Atlanta

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Emory University (Winship Cancer Institute)

Live official records

Open in full search

Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Interventions: Buloxibutid, Placebo; Drug
Lead sponsor: Vicore Pharma AB; Industry
Eligibility: 40 Years and older
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Redding, California • Sacramento, California + 19 more

Conditions: Crohn's Disease
Interventions: TAK-279, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 30
States / cities: Murrieta, California • Orange, California • Clearwater, Florida + 27 more

Conditions: Mitral Regurgitation (MR)
Interventions: Mitral Valve Repair including the use of Force Feedback instruments; Device
Lead sponsor: Intuitive Surgical; Industry
Eligibility: 22 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Atlanta, Georgia • New York, New York • Spokane, Washington

Conditions: Spinal Cord Injury
Interventions: transcranial direct current stimulation (tDCS) + FTP, transcranial pulsed current stimulation (tPCS) + FTP, transcranial random noise stimulation (tRNS) + FTP, sham transcranial electrical stimulation (tES) + FTP; Other
Lead sponsor: Shepherd Center, Atlanta GA; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Stress Disorders, Post-Traumatic
Interventions: tcVNS, sham; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Cytomegalovirus (CMV), Kidney Transplant; Complications, Kidney Diseases
Interventions: Valganciclovir (Pre-emptive CMV Therapy), Valganciclovir CMV Prophylaxis; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 8
States / cities: San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more

Conditions: Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
Interventions: MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX; Drug · Combination Product
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 31
States / cities: La Jolla, California • Los Angeles, California • San Diego, California + 25 more

Conditions: Major Depressive Disorder
Interventions: NBI-1065845; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 49
States / cities: Huntsville, Alabama • Bryant, Arkansas • Little Rock, Arkansas + 42 more

Conditions: Clear Cell Renal Cell Carcinoma, Solid Tumors
Interventions: casdatifan, Cabozantinib, Zimberelimab, Ipilimumab; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 20
States / cities: Birmingham, Alabama • San Diego, California • Santa Monica, California + 13 more

Conditions: Migraine
Interventions: Elismetrep, Placebo; Drug
Lead sponsor: TriGemX Bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 72
States / cities: Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 64 more

Conditions: Poor Sleep Quality, Leg Cramps, Nocturnal, Melatonin, Magnesium, Muscle Cramps
Interventions: Magnesium and melatonin based multi-ingredient dietary supplementation, Placebo; Dietary Supplement · Other
Lead sponsor: StudySetGo; Network
Eligibility: 40 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 7
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Palm Beach Gardens, Florida + 4 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Petosemtamab, Pembrolizumab; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 699 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 36
States / cities: Mobile, Alabama • La Jolla, California • Los Angeles, California + 30 more

Clinical trials in Atlanta, Georgia

Filter and sort this location

Institutions in Atlanta

Live official records

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Use of Force Feedback Instruments With the da Vinci Surgical System, Model IS5000 for Mitral Valve Repair

Influence of Transcranial Electrical Stimulation on Arm and Hand Function After Cervical Spinal Cord Injury

Transcutaneous Vagal Nerve Stimulation in Veterans With Posttraumatic Stress Disorder

Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

The Effect of a Daily Magnesium and Melatonin Supplement on Sleep Quality in People With Nighttime Leg Cramps

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)